Melanoma News and Research RSS Feed - Melanoma News and Research

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active. [More]
Study finds link between citrus fruit consumption and melanoma risk

Study finds link between citrus fruit consumption and melanoma risk

A new analysis of two long-term studies has revealed a potential association between malignant melanoma risk and frequent consumption of grapefruit and oranges. The study found that compared with people who consumed these fruits less than twice a week, those who had them at least 1.6 times a day were at a 36% higher risk of developing melanoma. [More]
Frequent consumption of citrus fruits may increase risk of skin cancer

Frequent consumption of citrus fruits may increase risk of skin cancer

A new analysis of dietary patterns among more than 100,000 Americans suggests that frequent consumption of citrus -- namely whole grapefruit and orange juice -- may be associated with an increased risk of melanoma. [More]
Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research. [More]
Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Researchers in the United Kingdom and Denmark have studied the "see-through" larvae of zebrafish to reveal how wound healing leads to skin cancer. Live imaging shows neutrophils, the protective inflammatory cells of the body's immune system, diverted from an induced wound to any nearby precancerous skin cells. [More]
New discovery could lead to personalized treatment for colon cancer

New discovery could lead to personalized treatment for colon cancer

A UNC Lineberger Comprehensive Cancer Center discovery of just how a certain tumor suppressor molecule works to prevent tumor growth could lead to a personalized treatment approach for colon cancer. [More]
Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. [More]
CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada is informing Canadians that eight unauthorized health products (listed in the table below) were seized from Better Bodies Supplements, 118 Main Street North, in Airdrie, Alta. [More]
Discovery sheds light on how the Hippo pathway maintains cellular balance

Discovery sheds light on how the Hippo pathway maintains cellular balance

Researchers at University of California, San Diego School of Medicine have discovered a self-regulating loop in the Hippo pathway, a signaling channel garnering increased attention from cancer researchers due to its role in controlling organ size, cell proliferation and cell death. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
UAlberta partnership could transform cancer treatment, improve patient outcomes

UAlberta partnership could transform cancer treatment, improve patient outcomes

A multimillion dollar research partnership announced today at the University of Alberta is giving a "dream team" of researchers the opportunity to potentially transform cancer treatment and better patient outcomes. [More]
Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration. [More]
STAR tumor ablation system reduces pain from spinal tumors, improves quality of life

STAR tumor ablation system reduces pain from spinal tumors, improves quality of life

Many patients with advanced cancers experience significant pain, and the pain caused by metastases (cancers that have spread to the spine) can be excruciating as tumor growth replaces bone. [More]
Myriad Genetics, Chris4Life launch educational campaign to teach individuals about risk of hereditary cancer

Myriad Genetics, Chris4Life launch educational campaign to teach individuals about risk of hereditary cancer

Chris4Life Colon Cancer Foundation, a Washington, D.C.-based national non-profit organization, and Myriad Genetics, a leader in personalized medicine, today announced their “What’s Your History” family history week (June 24-30, 2015). [More]
Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic. [More]
Drugs used against impotence does not increase risk of malignant melanoma

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association. [More]
PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations. [More]
UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas. [More]
Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine. [More]
Advertisement
Advertisement